CGYO18021 / NRG-GY009 / Richard MooreResearch Question:
What are good and bad effects of adding atezolizumab to the usual chemotherapy (liposomal
doxorubicin) and to the usual chemotherapy with bevacizumab?
Basic Study Information
Purpose:Location: Cancer Center
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride
with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian
tube, or primary peritoneal cancer that has come back (recurrent). Chemotherapy drugs,
such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such
as atezolizumab and bevacizumab, may help the body's immune system attack the cancer,
and may interfere with the ability of tumor cells to grow and spread. It is not yet
known which combination will work better in treating patients with ovarian, fallopian
tube, or primary peritoneal cancer.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02839707?term=GY009&rank=1
Study Reference #: CGYO18021
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Amber Johnson
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search